Emcure Pharma IPO Description – Emcure Pharmaceuticals stands as a prominent Indian pharmaceutical entity, dedicated to the advancement, production, and global promotion of an extensive array of pharmaceutical products spanning various critical therapeutic domains. Functioning as a research and development (R&D) oriented enterprise, Emcure boasts a distinct product portfolio encompassing oral medications, injectables, and biotherapeutics. This diverse range has facilitated its market penetration into over 70 countries, establishing a robust presence in India, Europe, and Canada.
The company has been ranked 13th in domestic sales among pharmaceutical companies in India for MAT FY 2024 and 4th in market share in its covered markets for the same period. Additionally, it is the leading pharmaceutical company in gynecology and HIV antiviral therapeutic areas for the MAT FY 2024. As of 31 March 2024, the company had a team of 548 qualified scientists and five dedicated R&D facilities in India. In addition, as of the same date, Emcure Pharmaceuticals had been granted 220 patents had 30 pending patent applications in several countries, and had submitted 102 drug master files (DMFs) for APIs with the U.S. Food and Drug Administration (USFDA).
Emcure Pharmaceuticals has 13 manufacturing facilities across India. The company has witnessed substantial sales expansion in India over the recent years. Its sales in India accounted for 48.28% of the total revenue from operations during FY 2024.
Promoters of Emcure Pharma – Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta
Table of Contents
Emcure Pharmaceuticals IPO Details
| Emcure Pharma IPO Dates | 3 – 5 July 2024 |
| Emcure Pharma Issue Price | INR 960 – 1,008 per share (Employee Discount – INR 90 per share) |
| Fresh issue | INR 800 crore |
| Offer For Sale | 1,14,28,839 shares (INR 1,097.17 – 1,152.03 crore) |
| Total IPO size | INR 1,952.03 crore |
| Minimum bid (lot size) | 14 shares (INR 14,112) |
| Face Value | INR 10 per share |
| Retail Allocation | 35% |
| Listing On | BSE, NSE |
Emcure Pharma’s Financial Performance
| FY 2022 | FY 2023 | FY 2024 | |
| Revenue | 5,855.39 | 5,985.81 | 6,658.25 |
| Expenses | 4,946.31 | 5,278.36 | 5,978.08 |
| Net income | 702.56 | 561.85 | 527.58 |
| Margin (%) | 12.00 | 9.39 | 7.92 |
Emcure Pharma IPO News
Emcure Pharma Valuations & Margins
| FY 2022 | FY 2023 | FY 2024 (Pre Issue) | FY 2024 (Post-Issue)* | |
| EPS | 36.55 | 29.36 | 27.49 | 26.34 |
| PE Ratio | – | – | 34.92 – 36.66 | 36.44 – 38.26 |
| FY 2022 | FY 2023 | FY 2024 | |
| RONW (%) | 33.32 | 21.27 | 16.87 |
| NAV | 109.69 | 138.03 | 162.93 |
| ROCE (%) | 29.69 | 22.01 | 19.37 |
| EBITDA (%) | 23.54 | 20.24 | 19.01 |
| Debt/Equity | 0.99 | 0.83 | 0.67 |
Emcure Pharma IPO GMP Today (Daily Trend)
| Date | Day-wise IPO GMP | Kostak | Subject to Sauda |
| 9 July 2024 | 360 | – | 3,900 |
| 8 July 2024 | 365 | – | 4,100 |
| 6 July 2024 | 355 | – | 3,900 |
| 5 July 2024 | 320 | – | 3,500 |
| 4 July 2024 | 310 | – | 3,500 |
| 3 July 2024 | 282 | – | 3,300 |
| 2 July 2024 | 275 | – | 3,200 |
| 1 July 2024 | 260 | – | 2,900 |
| 29 June 2024 | 250 | – | 3,000 |
Emcure Pharma IPO Objectives
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company – INR 600 crore
- General corporate purposes
Emcure Pharma – Comparison With Listed Peers
| Company | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Emcure Pharmaceuticals | 36.66 | 27.49 | 16.87 | 162.93 | 6,658.25 |
| Dr. Reddy’s Laboratories | 17.93 | 334.59 | 19.74 | 1,693.75 | 28,011.10 |
| Cipla Limited | 30.10 | 51.01 | 15.43 | 330.78 | 25,774.09 |
| Alkem Laboratories | 33.86 | 150.19 | 17.41 | 862.46 | 12,667.58 |
| Torrent Pharmaceuticals | 57.74 | 48.94 | 24.15 | 202.57 | 10,728.0 |
| Mankind Pharma | 45.30 | 47.68 | 20.43 | 233.73 | 10,334.78 |
| Abbott India | 47.43 | 565.28 | 32.48 | 1,740.71 | 5,848.91 |
| J. B. Chemicals & Pharmaceuticals | 50.49 | 35.66 | 18.90 | 188.37 | 3,484.18 |
Emcure Pharma IPO Dates & Listing Performance
| IPO Opening Date | 3 July 2024 |
| IPO Closing Date | 5 July 2024 |
| Finalisation of Basis of Allotment | 8 July 2024 |
| Initiation of refunds | 9 July 2024 |
| Transfer of shares to demat accounts | 9 July 2024 |
| Emcure Pharma IPO Listing Date | 10 July 2024 |
| Opening Price on NSE | INR 1,325.05 per share (up 31.45%) |
| Closing Price on NSE | INR 1,359.15 per share (up 34.84%) |
Emcure Pharma IPO Reviews – Subscribe or Avoid?
Ajcon Global – Subscribe
Anand Rathi – Subscribe
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research – Not rated
Asit C Mehta –
BP Wealth – Subscribe
Capital Market – Subscribe
Canara Bank Securities – Subscribe
Choice Broking – Subscribe
STOXBOX – Subscribe
Elite Wealth –
GCL Broking –
Geojit – Subscribe
GEPL Capital – Subscribe
Hem Securities – Subscribe
HENSEX Securities – Subscribe
Master Capital Services – Subscribe
Jainam Broking – Subscribe for long term
DR Choksey – Subscribe
SBI Securities – Subscribe for long term
Marwadi Financial – Subscribe
Mehta Equities – Subscribe for long term
Nirmal Bang – Subscribe
Reliance Securities – Subscribe
SMC Global – 2/5
Samco Securities – Subscribe for listing gains
Sushil Finance – Subscribe for medium term
Swastika Investmart – Subscribe
Ventura Securities – Subscribe
Emcure Pharma Offer Lead Manager
KOTAK MAHINDRA CAPITAL COMPANY LIMITED
27 BKC, 1st Floor, Plot no. C-27,
‘G’ Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051
Phone: +91 22 4336 0000
Email: [email protected]
Website: www.investmentbank.kotak.com
Emcure Pharma Offer Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai 400 083, Maharashtra, India
Phone: +91 810 811 4949
Email: [email protected]
Website: www.linkintime.co.in
Emcure Pharma Contact Details
EMCURE PHARMACEUTICALS LIMITED
Plot No. P-1 and P-2, IT-BT Park, Phase II,
M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra
Phone: +91 20 3507 0033, +91 20 3507 0000
Email: [email protected]
Website: www.emcure.com
Emcure Pharma IPO FAQs
How many shares in Emcure Pharma IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Emcure Public Offer?
The best way to apply in Emcure public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Emcure Pharma IPO GMP today?
Emcure Pharma IPO GMP today is INR 360 per share.
What is Emcure IPO kostak rate today?
Emcure IPO kostak rate today is NA per application.
What is Emcure Pharma Subject to Sauda rate today?
Emcure Pharma Subject to Sauda rate today is INR 3,900 per application.
